<DOC>
	<DOCNO>NCT01728948</DOCNO>
	<brief_summary>This prospective , single arm , multi-center pilot study include 120 mRCC patient 65 year , prior systemic treatment , determine candidate systemic therapy investigator . The treatment Sorafenib comply recommendation write local product information . The primary endpoint overall survival . The secondary endpoint include effectiveness point , safety patient characteristic . With 120 completed patient , observed survival rate 12 month 60 % , width 95 % confidence interval approximately 18 % .</brief_summary>
	<brief_title>Sorafenib Elderly mRCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients histologically/cytologically diagnose metastasis RCC candidate systemic therapy decide accept Sorafenib treatment . &gt; =65 year age Patients sign informed consent Patients life expectancy â‰¥12 week No prior systemic treatment The approved local product label must follow exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>renal cell carcinoma ( RCC )</keyword>
	<keyword>elderly</keyword>
	<keyword>effectiveness</keyword>
	<keyword>safety</keyword>
</DOC>